Literature DB >> 28987260

Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.

Pegah Golabi1, Haley Bush1, Zobair M Younossi2.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is recognized as a global health problem and as a common cause of chronic liver disease. Nonalcoholic steatohepatitis (NASH) carries an increased risk for development of advanced liver disease. Lifestyle modifications with diet and exercise have been the initial management recommendation. However, these changes are difficult to achieve and sustain overtime. There are pharmacologic agents being considered for treatment of NASH. Some target insulin resistance and others focus on oxidative stress, inflammation, apoptosis, and fibrosis. There is a great deal of efforts to develop therapeutic regimens for patients with NASH and NASH with significant fibrosis.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clinical trials; NAFLD; NASH; Nonantifibrotics; Treatment

Mesh:

Substances:

Year:  2017        PMID: 28987260     DOI: 10.1016/j.cld.2017.06.010

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  10 in total

1.  Sex modulates hepatic mitochondrial adaptations to high-fat diet and physical activity.

Authors:  Colin S McCoin; Alex Von Schulze; Julie Allen; Kelly N Z Fuller; Qing Xia; Devin C Koestler; Claire J Houchen; Adrianna Maurer; Gerald W Dorn; Kartik Shankar; E Matthew Morris; John P Thyfault
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-04-30       Impact factor: 4.310

2.  Reduction of Liver Span and Parameters of Inflammation in Nonalcoholic Fatty Liver Disease Patients Treated with Lycosome Formulation of Phosphatidylcholine: A Preliminary Report.

Authors:  Ivan M Petyaev; Pavel Y Dovgalevsky; Natalia E Chalyk; Victor A Klochkov; Nigel H Kyle; Yuriy K Bashmakov
Journal:  Int J Chronic Dis       Date:  2018-04-01

3.  Exercise without dietary changes alleviates nonalcoholic fatty liver disease without weight loss benefits.

Authors:  Duck-Pil Ok; Kangeun Ko; Ju Yong Bae
Journal:  Lipids Health Dis       Date:  2018-09-01       Impact factor: 3.876

Review 4.  Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis.

Authors:  Mehmet Sayiner; Brian Lam; Pegah Golabi; Zobair M Younossi
Journal:  Therap Adv Gastroenterol       Date:  2018-11-15       Impact factor: 4.409

5.  Inhibition of Serotonin Synthesis Induces Negative Hepatic Lipid Balance.

Authors:  Jun Namkung; Ko Eun Shong; Hyeongseok Kim; Chang Myung Oh; Sangkyu Park; Hail Kim
Journal:  Diabetes Metab J       Date:  2018-04-25       Impact factor: 5.376

6.  A juvenile case with nonalcoholic steatohepatitis and traditional Korean medicine-based treatment.

Authors:  Chang-Gue Son
Journal:  Integr Med Res       Date:  2018-02-02

7.  Polyphenol-rich Trapa quadrispinosa pericarp extract ameliorates high-fat diet induced non-alcoholic fatty liver disease by regulating lipid metabolism and insulin resistance in mice.

Authors:  Tunyu Jian; Han Lü; Xiaoqin Ding; Yuexian Wu; Yuanyuan Zuo; Jiawei Li; Jian Chen; Hong Gu
Journal:  PeerJ       Date:  2019-11-29       Impact factor: 2.984

8.  Among Patients With NAFLD, Treatment of Dyslipidemia Does Not Reduce Cardiovascular Mortality.

Authors:  Omer Shahab; Rakesh Biswas; James Paik; Haley Bush; Pegah Golabi; Zobair M Younossi
Journal:  Hepatol Commun       Date:  2018-09-24

Review 9.  Obesity and nonalcoholic fatty liver disease: current perspectives.

Authors:  Raiya Sarwar; Nicholas Pierce; Sean Koppe
Journal:  Diabetes Metab Syndr Obes       Date:  2018-09-25       Impact factor: 3.168

10.  Reduced Oxidative Stress and Enhanced FGF21 Formation in Livers of Endurance-Exercised Rats with Diet-Induced NASH.

Authors:  Janin Henkel; Katja Buchheim-Dieckow; José P Castro; Thomas Laeger; Kristina Wardelmann; André Kleinridders; Korinna Jöhrens; Gerhard P Püschel
Journal:  Nutrients       Date:  2019-11-08       Impact factor: 5.717

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.